Evidence map›Paper›PMID 41445610›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Genetic risk in extremely early onset type 1 diabetes.

Amber M Luckett, Georgia Bonfield, Gareth Hawkes, Harry D Green, Lauric Ferrat, Clara Domingo-Vila, Timothy I M Tree, William A Hagopian, Bart O Roep, Michael N Weedon and 4 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Amber M LuckettDepartment of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, UK.ORCID 0000-0001-9496-3796
Georgia BonfieldDepartment of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, UK.
Gareth HawkesDepartment of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, UK.
Harry D GreenDepartment of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, UK.
Lauric FerratDepartment of Genetic Medicine and Development, Faculty of Medicine University of Geneva, Geneva.
Clara Domingo-VilaSchool of Immunology and Microbial Sciences, King's College London, London, UK.
Timothy I M TreeSchool of Immunology and Microbial Sciences, King's College London, London, UK.ORCID 0000-0002-6973-5377
William A HagopianDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, USA.
Bart O RoepDepartment of Internal Medicine, Cure One Type 1 Diabetes Center, Leiden University Medical Center, Leiden, the Netherlands.
Michael N WeedonDepartment of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, UK.
Matthew B JohnsonDepartment of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, UK.
Stephen S RichCenter for Public Health Genomics, University of Virginia, Virginia, USA.
Richard A OramDepartment of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, UK.
EXE-T1D consortium

Funding

Limited Competition: Continued Follow-up of Subjects and Initiation of a Second Case-control Cohort in The Environmental Determinants of Diabetes in The Young Study (TEDDY)U01DK128847 · NIDDK · UNIVERSITY OF SOUTH FLORIDA · PI JEFFREY P KRISCHER · 2021 to 2026
$79.2M
Type 1 Diabetes Genetics ConsortiumU01DK062418 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI RICH, STEPHEN S. · 2002 to 2007
$59.8M
Type 1 Diabetes Genetic Risk Score in TrialNetR01DK121843 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI REDONDO, MARIA JOSE · 2019 to 2023
$2.4M
NIDDK NIH HHS R01 DK121843NIDDK NIH HHS U01 DK062418NIDDK NIH HHS U01 DK128847
6 · The paper itself

Abstract

Identifying individuals at risk of early onset type 1 diabetes (diagnosed <2 years) would be highly beneficial in reducing risk of severe diabetic ketoacidosis (DKA) for those with extreme autoimmunity. We aimed to investigate whether genetic variation contributes to heterogeneity in age of type 1 diabetes onset, focusing on those diagnosed <2 years and ages previously defined by histological differences. We carried out association testing on 6773 individuals with type 1 diabetes and tested for heterogeneity in Human Leukocyte Antigen (HLA) variants across stratified age groups (594 diagnosed <2 years, 2241 diagnosed 2-7 years, 3094 diagnosed 7-13 years, 844 diagnosed 13+ years). We used a 67 SNP type 1 diabetes genetic risk score (T1D-GRS) to quantify aggregated genetic risk and assessed its utility in screening for type 1 diabetes <2 years. We observed higher T1D-GRSs as age of onset decreased in type 1 diabetes and found that DR3-DQ2 homozygosity was most strongly associated with <2 years onset (log-OR=4.27). The T1D-GRS showed high discriminative ability for <2 years onset type 1 diabetes onset (AUC=0.94) and correctly identified 88% of type 1 diabetes cases at the 85th population centile. We have shown higher genetic risk for very early onset T1D and suggest T1D-GRSs in newborn screening is likely to be particularly sensitive to those with younger type 1 diabetes onset.

Identifiers

PMID41445610
PMCPMC12723774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.